NVAX Novavax Inc

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

$157.80  -25.81 (-14.06%)
As of 03/04/2021 15:59:50 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Large cap
Health Care
Biotechnology
USA
USA
12/05/1995
73,858,882
3,717,562
$13,561,229,324
0.00%
SEC Edgar Online
10-Q
10-K
670002401
US6700024010
BJDQXG4

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-49.76
108.58
66.23
-256.04%
-133.10%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy